Rhenman & Partners Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-120,000	Closed	-$348K	–	119
2017 Q2	$348K	Hold	120,000	–	–	0.05%	97
2017 Q1	$413K	Hold	120,000	–	–	0.07%	89
2016 Q4	$209K	Hold	120,000	–	–	0.04%	104
2016 Q3	$398K	Hold	120,000	–	–	0.06%	93
2016 Q2	$516K	Hold	120,000	–	–	0.09%	90
2016 Q1	$675K	Buy	120,000 +1,100	+0.9%	+$14.3K	0.13%	89
2015 Q4	$2.04M	Hold	118,900	–	–	0.31%	86
2015 Q3	$2.51M	Buy	118,900 +40,000	+51%	+$1.37M	0.4%	68
2015 Q2	$3.91M	Sell	78,900 -4,280	-5%	-$256K	0.47%	72
2015 Q1	$6.51M	Buy	83,180 +45,680	+122%	+$2.83M	1.1%	32
2014 Q4	$2.27M	Sell	37,500 -11,900	-24%	-$598K	0.66%	67
2014 Q3	$2.1M	Buy	49,400 +19,380	+65%	+$1.04M	0.62%	63
2014 Q2	$1.85M	Sell	30,020 -2,900	-9%	-$169K	0.55%	65
2014 Q1	$2.14M	Buy	32,920 +7,920	+32%	+$536K	0.64%	57
2013 Q4	$1.41M	Buy	+25,000	New	+$1.4M	0.55%	72

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rhenman & Partners Asset Management's OREX Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 120,000 shares — an estimated $348K sold.

Rhenman & Partners Asset Management first reported a position in OREX in Q4 2013 and held it in 15 quarters. The position peaked at $6.51M in Q1 2015. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 120,000 Orexigen Therapeutics, Inc. shares in Q3 2017, an estimated $348K.
Rhenman & Partners Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 15 quarters.
Rhenman & Partners Asset Management's Orexigen Therapeutics, Inc. position peaked at $6.51M in Q1 2015.
42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.